前列腺组织中的他汀浓度具有亚型与剂量依赖性
研究首次比较亲脂性与亲水性他汀在前列腺组织中的浓度,纳入1993至2019年间接受根治性前列腺切除术且服用阿托伐他汀或瑞舒伐他汀的80例患者,用HPLC-质谱法测定血清与前列腺组织他汀浓度。瑞舒伐他汀中位组织浓度高于阿托伐他汀(3.98 ng/g vs 0.96 ng/g,P<.001),且两种他汀均观察到剂量依赖性。
要点
- 瑞舒伐他汀中位前列腺组织浓度高于阿托伐他汀(3.98 ng/g vs 0.96 ng/g,P<.001)。
- 高剂量较低剂量在中位前列腺浓度上更高:阿托伐他汀1.22 ng/g vs 0.79 ng/g(P=.69),瑞舒伐他汀5.21 ng/g vs 1.99 ng/g(P<.001)。
- 前列腺组织中可测到他汀浓度的患者比例:阿托伐他汀15例(38.4%),瑞舒伐他汀22例(53.6%)。
核心结论
- 首次显示亲脂性与亲水性他汀均可在前列腺癌患者前列腺中测得,且浓度具有剂量依赖性。
- 亲水性他汀瑞舒伐他汀在前列腺中达到的浓度约为阿托伐他汀的4倍。
研究设计与样本
- 回顾1993至2019年间接受根治性前列腺切除术的所有患者,选取80例服用阿托伐他汀(亲脂性)或瑞舒伐他汀(亲水性)控制胆固醇且有库存新鲜冷冻前列腺切除标本的患者。
- 主要终点为用HPLC-质谱法测定的血清与前列腺他汀浓度。
- 采用Mann-Whitney U检验比较阿托伐他汀与瑞舒伐他汀组、高剂量与低剂量组之间的血清/前列腺他汀浓度。
主要发现
- 39例服用阿托伐他汀,41例服用瑞舒伐他汀;38例服用高剂量他汀,42例服用低剂量他汀。
- 前列腺组织中可测到他汀浓度者:阿托伐他汀组15例(38.4%,高剂量33.3% vs 低剂量42.8%),瑞舒伐他汀组22例(53.6%,高剂量55% vs 低剂量52.3%)。
- 瑞舒伐他汀中位组织浓度高于阿托伐他汀(3.98 ng/g vs 0.96 ng/g,P<.001)。
- 高剂量较低剂量中位前列腺浓度更高:阿托伐他汀1.22 ng/g vs 0.79 ng/g(P=.69),瑞舒伐他汀5.21 ng/g vs 1.99 ng/g(P<.001)。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate for the first time, comparative serum and prostate tissue concentrations of lipophilic and hydrophilic statins. METHODS: After reviewing all patients who underwent radical prostatectomy between 1993 and 2019, we selected 80 patients taking atorvastatin (lipophilic) or rosuvastatin (hydrophilic) for cholesterol control and with available banked fresh-frozen tissue from the prostatectomy. Primary endpoint was serum and prostate statin concentration measured by HPLC-mass spectrometry analysis. Serum/prostate statin concentrations were compared between patients on atorvastatin and rosuvastatin, and patients receiving high- and low-dose statin, using the Mann-Whitney U test. RESULTS: In total, 39 patients were taking atorvastatin and 41 were taking rosuvastatin. Thirty-eight and 42 were taking high- and low-dose statin, respectively. Statin concentration was measurable in the prostatic tissue of 15 patients (38.4%) taking atorvastatin (33.3% high-dose vs 42.8% low-dose) compared to 22 (53.6%) taking rosuvastatin (55% high-dose vs 52.3% low-dose). Median tissue concentration of rosuvastatin was greater than atorvastatin (3.98 ng/g vs 0.96 ng/g, P <.001). Dose-dependency was observed: median prostate concentration was higher in those taking high-dose versus low-dose statin for both atorvastatin (1.22 ng/g vs 0.79 ng/g, P = .69) and rosuvastatin (5.21 ng/g vs 1.99 ng/g, P <.001). CONCLUSION: We have shown, for the first time, that lipophilic and hydrophilic statins can be measured in the prostate of patients with prostate cancer and that the concentrations are dependent on dose. Moreover, rosuvastatin, a hydrophilic statin, achieves a 4-fold higher concentration in the prostate.
引用
- Chavarriaga J, Penn LZ, Khurram N, et al. Statin Concentration in Prostatic Tissue is Subtype- and Dose-dependent. Urology. 2024. PMID: 39222671. doi:10.1016/j.urology.2024.08.059
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。